-
Je něco špatně v tomto záznamu ?
Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience
M. Slavik, P. Burkon, T. Kazda, M. Budikova, M. Slavikova, E. Dvorakova, P. Pospisil, J. Gombosova, P. Navratilova, P. Slampa,
Jazyk angličtina Země Slovensko
Typ dokumentu časopisecké články, práce podpořená grantem
Odkazy
PubMed
25150311
DOI
10.4149/neo_2014_081
Knihovny.cz E-zdroje
- MeSH
- adjuvantní chemoradioterapie * škodlivé účinky MeSH
- časové faktory MeSH
- dospělí MeSH
- gastroezofageální junkce * MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory jícnu mortalita terapie MeSH
- nádory žaludku mortalita terapie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan- Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023100
- 003
- CZ-PrNML
- 005
- 20191014110441.0
- 007
- ta
- 008
- 150709s2014 xo f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2014_081 $2 doi
- 035 __
- $a (PubMed)25150311
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Slavik, M $u Department of Radiation Oncology, Faculty of Medicine, MasarykUniversity and Masaryk Memorial Cancer Institute, Brno, Czech Republic.
- 245 10
- $a Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience / $c M. Slavik, P. Burkon, T. Kazda, M. Budikova, M. Slavikova, E. Dvorakova, P. Pospisil, J. Gombosova, P. Navratilova, P. Slampa,
- 520 9_
- $a Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan- Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a adjuvantní chemoradioterapie $x škodlivé účinky $7 D059186
- 650 _2
- $a nádory jícnu $x mortalita $x terapie $7 D004938
- 650 12
- $a gastroezofageální junkce $7 D004943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory žaludku $x mortalita $x terapie $7 D013274
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Burkon, P
- 700 1_
- $a Kazda, Tomáš $7 xx0213412
- 700 1_
- $a Budikova, M
- 700 1_
- $a Slavikova, M
- 700 1_
- $a Dvorakova, E
- 700 1_
- $a Pospisil, P
- 700 1_
- $a Gombosova, J
- 700 1_
- $a Navratilova, P
- 700 1_
- $a Slampa, P
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 61, č. 6 (2014), s. 739-46
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25150311 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20191014110905 $b ABA008
- 999 __
- $a ok $b bmc $g 1083438 $s 906093
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 61 $c 6 $d 739-46 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20150709